{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:48:49Z","timestamp":1760986129287,"version":"3.37.3"},"reference-count":105,"publisher":"Oxford University Press (OUP)","issue":"Supplement_C","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,18]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) with or without acute coronary syndromes (ACS) represent a subgroup with a challenging pharmacological management. Indeed, if on the one hand, antithrombotic therapy should reduce the risk related to recurrent ischaemic events and\/or stent thrombosis; on the other hand, care must be taken to avoid major bleeding events. In recent years, several trials, which overall included more than 12\u00a0000 patients, have been conducted demonstrating the safety of different therapeutic combinations of oral antiplatelet and anticoagulant agents. In the present ANMCO position paper, we propose a decision-making algorithm on antithrombotic strategies based on scientific evidence and expert consensus to be adopted in the periprocedural phase, at the time of hospital discharge, and in the long-term follow-up of patients with AF undergoing PCI with\/without ACS.<\/jats:p>","DOI":"10.1093\/eurheartj\/suac020","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T06:52:35Z","timestamp":1652943155000},"page":"C254-C271","source":"Crossref","is-referenced-by-count":5,"title":["ANMCO position paper on antithrombotic treatment of patients with atrial fibrillation undergoing intracoronary stenting and\/or acute coronary syndromes"],"prefix":"10.1093","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8552-1272","authenticated-orcid":false,"given":"Leonardo","family":"De Luca","sequence":"first","affiliation":[{"name":"Cardiology, Department of Cardio-Thoraco-Vascular, Azienda Ospedaliera San Camillo Forlanini, Circonvallazione Gianicolense, 87, 00152 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Rubboli","sequence":"additional","affiliation":[{"name":"Cardiology, Cardiovascular Department, Ospedale S. Maria delle Croci, Ravenna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maddalena","family":"Lettino","sequence":"additional","affiliation":[{"name":"Department of Cardiology, San Gerardo Hospital, ASST-Monza, Monza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Tubaro","sequence":"additional","affiliation":[{"name":"CCU, Intensive and Interventional Cardiology Department, P.O. San Filippo Neri, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Leonardi","sequence":"additional","affiliation":[{"name":"University of Pavia and IRCCS S. Matteo Foundation General Hospital, Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianni","family":"Casella","sequence":"additional","affiliation":[{"name":"Cardiology Department, Ospedale Maggiore, Azienda USL di Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serafina","family":"Valente","sequence":"additional","affiliation":[{"name":"Cardio-Thoracic Department, A.O.U. Senese, Ospedale Santa Maria alle Scotte, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Rossini","sequence":"additional","affiliation":[{"name":"Emergency Department and Critical Areas, Azienda Ospedaliera Santa Croce e Carle, Cuneo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Sciahbasi","sequence":"additional","affiliation":[{"name":"Cardiology Department, Ospedale Sandro Pertini, ASL RM2, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Natale","sequence":"additional","affiliation":[{"name":"Cardiology, Department of Cardio-Thoraco-Vascular, Azienda Ospedaliera San Camillo Forlanini, Circonvallazione Gianicolense, 87, 00152 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Trambaiolo","sequence":"additional","affiliation":[{"name":"Cardiology Department, Ospedale Sandro Pertini, ASL RM2, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Navazio","sequence":"additional","affiliation":[{"name":"Hospital Cardiology Department, Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manlio","family":"Cipriani","sequence":"additional","affiliation":[{"name":"Cardiology 2-Heart Failure and Transplants, Dipartimento Cardiotoracovascolare \u201cA. De Gasperis\u201d, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Corda","sequence":"additional","affiliation":[{"name":"Cardiology Department, Azienda Ospedaliera G. Brotzu, Cagliari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"De Nardo","sequence":"additional","affiliation":[{"name":"Cardiology-ICU Department, Ospedale Civile \u201cG. Jazzolino\u201d, Vibo Valentia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina Maura","family":"Francese","sequence":"additional","affiliation":[{"name":"Cardiology Department, Azienda di Rilievo Nazionale e Alta Specializzazione \u201cGaribaldi\u201d, Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cosimo","family":"Napoletano","sequence":"additional","affiliation":[{"name":"Cardiology-ICU Department\u2014Cath Lab, Presidio Ospedaliero \u201cG. Mazzini\u201d, Teramo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Tizzani","sequence":"additional","affiliation":[{"name":"Cardiology Department, Ospedale degli Infermi, Rivoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Nardi","sequence":"additional","affiliation":[{"name":"Cardiology Department, Ospedale Santo Spirito, Casale Monferrato (AL), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loris","family":"Roncon","sequence":"additional","affiliation":[{"name":"Cardiology Department, Ospedale Santa Maria della Misericordia, Rovigo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Caldarola","sequence":"additional","affiliation":[{"name":"Cardiology-ICU Department, Ospedale San Paolo, Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Riccio","sequence":"additional","affiliation":[{"name":"Follow-up of the Post-Acute Patient, Cardio-Vascular Department, AORN Sant'Anna and San Sebastiano, Caserta, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Gabrielli","sequence":"additional","affiliation":[{"name":"Cardiology, Department of Cardio-Thoraco-Vascular, Azienda Ospedaliera San Camillo Forlanini, Circonvallazione Gianicolense, 87, 00152 Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Oliva","sequence":"additional","affiliation":[{"name":"Cardiology 2-Heart Failure and Transplants, Dipartimento Cardiotoracovascolare \u201cA. De Gasperis\u201d, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Massimo Gulizia","sequence":"additional","affiliation":[{"name":"Heart Care Foundation, Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Furio","family":"Colivicchi","sequence":"additional","affiliation":[{"name":"Clinical and Rehabilitation Cardiology Department, Presidio Ospedaliero San Filippo Neri, ASL Roma 1, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"2022051906294101600_suac020-B1","doi-asserted-by":"crossref","first-page":"e24964","DOI":"10.1371\/journal.pone.0024964","article-title":"Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography","volume":"6","author":"Kralev","year":"2011","journal-title":"PLoS One"},{"key":"2022051906294101600_suac020-B2","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehn579","article-title":"Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications","volume":"30","author":"Schmitt","year":"2009","journal-title":"Eur Heart J"},{"key":"2022051906294101600_suac020-B3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2459\/JCM.0b013e328335233e","article-title":"Epidemiology and patterns of care of patients admitted to Italian Intensive Cardiac Care Units: the BLITZ-3 registry","volume":"11","author":"Casella","year":"2010","journal-title":"J Cardiovasc Med"},{"key":"2022051906294101600_suac020-B4","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11886-012-0289-3","article-title":"Atrial fibrillation and mortality in patients with acute myocardial infarction: a systematic overview and meta-analysis","volume":"14","author":"Angeli","year":"2012","journal-title":"Curr Cardiol Rep"},{"key":"2022051906294101600_suac020-B5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ijcard.2017.08.019","article-title":"Recent trends in management and outcome of patients with acute coronary syndromes and atrial fibrillation","volume":"248","author":"De Luca","year":"2017","journal-title":"Int J Cardiol"},{"key":"2022051906294101600_suac020-B6","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"2022051906294101600_suac020-B7","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"2022051906294101600_suac020-B8","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"2022051906294101600_suac020-B9","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"2022051906294101600_suac020-B10","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"2022051906294101600_suac020-B11","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ahj.2012.02.018","article-title":"Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial","volume":"163","author":"Leonardi","year":"2012","journal-title":"Am Heart J"},{"key":"2022051906294101600_suac020-B12","doi-asserted-by":"crossref","first-page":"e022125","DOI":"10.1161\/JAHA.121.022125","article-title":"Cangrelor: clinical data, contemporary use, and future perspectives","volume":"10","author":"De Luca","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2022051906294101600_suac020-B13","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1160\/TH09-04-0245","article-title":"Are glycoprotein inhibitors safe during percutaneous coronary intervention in patients on chronic warfarin treatment?","volume":"102","author":"Lahtela","year":"2009","journal-title":"Thromb Haemost"},{"key":"2022051906294101600_suac020-B14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.120.046928","article-title":"Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-segment-elevation myocardial infarction: primary results of the FABOLUS-FASTER trial","volume":"142","author":"Gargiulo","year":"2020","journal-title":"Circulation"},{"key":"2022051906294101600_suac020-B15","doi-asserted-by":"crossref","first-page":"e604","DOI":"10.1161\/CIR.0000000000000477","article-title":"Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association","volume":"135","author":"Raval","year":"2017","journal-title":"Circulation"},{"key":"2022051906294101600_suac020-B16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijcard.2016.08.089","article-title":"Meta-analysis of uninterrupted as compared to interrupted oral anticoagulation with or without bridging in patients undergoing coronary angiography with or without percutaneous coronary intervention","volume":"223","author":"Kowalewski","year":"2016","journal-title":"Int J Cardiol"},{"key":"2022051906294101600_suac020-B17","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1160\/TH15-01-0061","article-title":"Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial","volume":"114","author":"Vranckx","year":"2015","journal-title":"Thromb Haemost"},{"key":"2022051906294101600_suac020-B18","doi-asserted-by":"crossref","first-page":"e001677","DOI":"10.1136\/openhrt-2021-001677","article-title":"Is percutaneous coronary intervention safe during uninterrupted direct oral anticoagulant therapy in patients with atrial fibrillation and acute coronary syndromes?","volume":"8","author":"De Luca","year":"2021","journal-title":"Open Heart"},{"key":"2022051906294101600_suac020-B19","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"2022051906294101600_suac020-B20","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4244\/EIJV8I9A162","article-title":"A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients","volume":"8","author":"Vranckx","year":"2013","journal-title":"Eurointervention"},{"key":"2022051906294101600_suac020-B21","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators","volume":"339","author":"Leon","year":"1998","journal-title":"N Engl J Med"},{"key":"2022051906294101600_suac020-B22","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Sch\u00f6mig","year":"1996","journal-title":"N Engl J Med"},{"key":"2022051906294101600_suac020-B23","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","year":"2006","journal-title":"Lancet"},{"key":"2022051906294101600_suac020-B24","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/eurheartj\/ehq117","article-title":"Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing coronary stenting: executive summary\u2013a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)","volume":"31","author":"Lip","year":"2010","journal-title":"Eur Heart J"},{"key":"2022051906294101600_suac020-B25","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2022051906294101600_suac020-B26","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/bcp.14127","article-title":"Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review","volume":"86","author":"Santos","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2022051906294101600_suac020-B27","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"2022051906294101600_suac020-B28","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022051906294101600_suac020-B29","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","article-title":"Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials","volume":"40","author":"","year":"2019","journal-title":"Eur Heart J"},{"key":"2022051906294101600_suac020-B30","first-page":"100524","article-title":"Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS\/PCI: a critical appraisal","volume":"28","author":"Galli","year":"2020","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2022051906294101600_suac020-B31","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2796.2008.01989.x","article-title":"Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation","volume":"264","author":"Sarafoff","year":"2008","journal-title":"J Intern Med"},{"key":"2022051906294101600_suac020-B32","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.amjcard.2009.03.053","article-title":"Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral antiCOagulants [STENTICO])","volume":"104","author":"Gilard","year":"2009","journal-title":"Am J Cardiol"},{"key":"2022051906294101600_suac020-B33","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1136\/hrt.2009.167064","article-title":"Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study","volume":"95","author":"Sambola","year":"2009","journal-title":"Heart"},{"key":"2022051906294101600_suac020-B34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/clc.22254","article-title":"One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry","volume":"37","author":"Rubboli","year":"2014","journal-title":"Clin Cardiol"},{"key":"2022051906294101600_suac020-B35","first-page":"563","article-title":"Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry","volume":"26","author":"Rubboli","year":"2014","journal-title":"J Invasive Cardiol"},{"key":"2022051906294101600_suac020-B36","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1253\/circj.CJ-15-0923","article-title":"Effects of triple therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention regarding thromboembolic risk stratification","volume":"80","author":"Sambola","year":"2016","journal-title":"Circ J"},{"key":"2022051906294101600_suac020-B37","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s12928-019-00589-7","article-title":"A prospective interventional registry of short-term dual-antiplatelet treatment after implantation of drug-eluting stents in patients with atrial fibrillation requiring oral anticoagulation therapy","volume":"35","author":"Horie","year":"2020","journal-title":"Cardiovasc Interv Ther"},{"key":"2022051906294101600_suac020-B38","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.cjco.2021.04.002","article-title":"Evolution of antithrombotic management of atrial fibrillation after percutaneous coronary intervention over 10 years and guidelines uptake","volume":"3","author":"Beaulieu","year":"2021","journal-title":"CJC Open"},{"key":"2022051906294101600_suac020-B39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10557-020-07090-x","article-title":"Trends of antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the GReek-AntiPlatElet Atrial Fibrillation (GRAPE-AF) registry","volume":"35","author":"Benetou","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"2022051906294101600_suac020-B40","doi-asserted-by":"crossref","first-page":"e041044","DOI":"10.1136\/bmjopen-2020-041044","article-title":"Antithrombotic management of patients with acute coronary syndrome and atrial fibrillation undergoing coronary stenting: a prospective, observational, nationwide study","volume":"10","author":"De Luca","year":"2020","journal-title":"BMJ Open"},{"key":"2022051906294101600_suac020-B41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2021.03.029","article-title":"Post-discharge antithrombotic management and clinical outcomes of patients with new-onset or pre-existing atrial fibrillation and acute coronary syndromes undergoing coronary stenting: follow-up data of the MATADOR-PCI study","volume":"88","author":"De Luca","year":"2021","journal-title":"Eur J Intern Med"},{"key":"2022051906294101600_suac020-B42","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention","volume":"62","author":"Lamberts","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022051906294101600_suac020-B43","doi-asserted-by":"crossref","first-page":"e007604","DOI":"10.1161\/CIRCINTERVENTIONS.118.007604","article-title":"Site variation and outcomes for antithrombotic therapy in atrial fibrillation patients after percutaneous coronary intervention","volume":"12","author":"Olivier","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"2022051906294101600_suac020-B44","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/ehjcvp\/pvx033","article-title":"Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"4","author":"Batra","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2022051906294101600_suac020-B45","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/ehjcvp\/pvaa088","article-title":"Combinations of antithrombotic therapies prescribed after percutaneous coronary intervention in patients with acute coronary syndromes and atrial fibrillation: data from the nationwide MATADOR-PCI registry","volume":"7","author":"De Luca","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2022051906294101600_suac020-B46","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.jacc.2018.07.054","article-title":"Combining oral anticoagulants with platelet inhibitors in patients with atrial fibrillation and coronary disease","volume":"72","author":"Sindet-Pedersen","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022051906294101600_suac020-B47","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group.","year":"2021","journal-title":"Eur Heart J"},{"key":"2022051906294101600_suac020-B48","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1136\/heartjnl-2017-312228","article-title":"Triple antithrombotic therapy after ACS and PCI in patients on chronic oral anticoagulation: update","volume":"104","author":"Capodanno","year":"2018","journal-title":"Heart"},{"key":"2022051906294101600_suac020-B49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2019.05.016","article-title":"Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC state-of-the-art review","volume":"74","author":"Capodanno","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022051906294101600_suac020-B50","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American Perspective: 2021 Update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"key":"2022051906294101600_suac020-B51","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","article-title":"2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease","volume":"77","author":"Kumbhani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2022051906294101600_suac020-B52","first-page":"512","article-title":"Antithrombotic strategies in patients with atrial fibrillation and acute coronary syndromes undergoing percutaneous coronary intervention","author":"De Luca L, Mistrulli R, Veneziano FA, Grigioni F, Volpe M, Musumeci F, Gabrielli D.","year":"2022","journal-title":"J Clin Med"},{"key":"2022051906294101600_suac020-B53","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.amjcard.2015.08.049","article-title":"Stroke risk factors beyond the CHA(2)DS(2)-VASc score: can we improve our identification of \u2018high stroke risk\u2019 patients with atrial fibrillation?","volume":"116","author":"Szymanski","year":"2015","journal-title":"Am J Cardiol"},{"key":"2022051906294101600_suac020-B54","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"2022051906294101600_suac020-B55","doi-asserted-by":"crossref","first-page":"e000250","DOI":"10.1161\/JAHA.113.000250","article-title":"A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score","volume":"2","author":"Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N, Reynolds K, Go AS.","year":"2013","journal-title":"J Am Heart Associat"},{"key":"2022051906294101600_suac020-B56","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1161\/CIRCULATIONAHA.118.038312","article-title":"Performance of the ABC scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48","volume":"139","author":"Berg","year":"2019","journal-title":"Circulation"},{"key":"2022051906294101600_suac020-B57","doi-asserted-by":"crossref","first-page":"e017157","DOI":"10.1136\/bmjopen-2017-017157","article-title":"Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation","volume":"7","author":"Fox","year":"2017","journal-title":"BMJ Open"},{"key":"2022051906294101600_suac020-B58","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacc.2017.10.085","article-title":"Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation","volume":"71","author":"Chao","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022051906294101600_suac020-B59","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-21-00165","article-title":"A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial","author":"Zwart B, Bor WL, de Veer AJWM, Mahmoodi BK, Kelder JC, Lip GYH, Bhatt DL, Cannon CP, Ten Berg JM.","year":"2022","journal-title":"Eurointervention"},{"key":"2022051906294101600_suac020-B60","doi-asserted-by":"publisher","DOI":"10.1159\/000521673","article-title":"Could the PARIS risk scores be useful for the choice of triple vs dual antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention?","author":"De Luca","year":"2022","journal-title":"Cardiology"},{"key":"2022051906294101600_suac020-B61","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jcin.2014.05.016","article-title":"Stent thrombosis: a clinical perspective","volume":"7","author":"Claessen","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"2022051906294101600_suac020-B62","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/CIRCULATIONAHA.108.828541","article-title":"Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC\/AHA Guidelines) bleeding score","volume":"119","author":"Subherwal","year":"2009","journal-title":"Circulation"},{"key":"2022051906294101600_suac020-B63","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jacc.2009.09.076","article-title":"A risk score to predict bleeding in patients with acute coronary syndromes","volume":"55","author":"Mehran","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2022051906294101600_suac020-B64","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"2022051906294101600_suac020-B65","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2021.2007870","article-title":"Predictive performance of different bleeding risk scores in patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary","author":"Lyu","year":"2022","journal-title":"Platelets"},{"key":"2022051906294101600_suac020-B66","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk","volume":"40","author":"Urban","year":"2019","journal-title":"Eur Heart J"},{"key":"2022051906294101600_suac020-B67","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1016\/j.jacc.2020.03.070","article-title":"Validation of the academic research consortium high bleeding risk definition in contemporary PCI patients","volume":"75","author":"Cao","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022051906294101600_suac020-B68","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1161\/CIRCULATIONAHA.120.046534","article-title":"Risk\/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS","volume":"141","author":"Alexander","year":"2020","journal-title":"Circulation"},{"key":"2022051906294101600_suac020-B69","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jacc.2021.11.035","article-title":"Antithrombotic therapy in patients with atrial fibrillation after acute coronary syndromes or percutaneous intervention","volume":"79","author":"Harskamp","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2022051906294101600_suac020-B70","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1093\/eurheartj\/ehaa906","article-title":"Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation","volume":"42","author":"Verdecchia","year":"2021","journal-title":"Eur Heart J"},{"key":"2022051906294101600_suac020-B71","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehz059","article-title":"Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial","volume":"40","author":"Oldgren","year":"2019","journal-title":"Eur Heart J"},{"key":"2022051906294101600_suac020-B72","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40256-020-00436-8","article-title":"Meta-analysis comparing potent oral P2Y12 inhibitors versus clopidogrel in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"21","author":"Casula","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"2022051906294101600_suac020-B73","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2022051906294101600_suac020-B74","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2022051906294101600_suac020-B75","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2022051906294101600_suac020-B76","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2022051906294101600_suac020-B77","doi-asserted-by":"crossref","first-page":"e0128492","DOI":"10.1371\/journal.pone.0128492","article-title":"Renal Impairment and prognosis of patients with atrial fibrillation undergoing coronary intervention\u2014the AFCAS trial","volume":"10","author":"Lahtela","year":"2015","journal-title":"PLoS One"},{"key":"2022051906294101600_suac020-B78","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"2022051906294101600_suac020-B79","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"key":"2022051906294101600_suac020-B80","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"2022051906294101600_suac020-B81","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s11239-021-02577-2","article-title":"One-year clinical outcome of patients with left ventricular thrombus after acute myocardial infarction discharged on triple or dual antithrombotic therapy","volume":"53","author":"De Luca","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"2022051906294101600_suac020-B82","doi-asserted-by":"crossref","first-page":"520","DOI":"10.21037\/atm-20-7839","article-title":"Management of left ventricular thrombus: a narrative review","volume":"9","author":"Rodriguez","year":"2021","journal-title":"Ann Transl Med"},{"key":"2022051906294101600_suac020-B83","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/jamacardio.2020.0652","article-title":"Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi","volume":"5","author":"Robinson","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2022051906294101600_suac020-B84","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/STR.0b013e3181f7d043","article-title":"Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"42","author":"Furie","year":"2011","journal-title":"Stroke"},{"key":"2022051906294101600_suac020-B85","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/ehjcvp\/pvaa027","article-title":"Long-term prognosis of de novo atrial fibrillation during acute myocardial infarction: the impact of anti-thrombotic treatment strategies","volume":"7","author":"Hofer","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2022051906294101600_suac020-B86","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.ejim.2017.01.003","article-title":"New-onset atrial fibrillation after percutaneous coronary intervention with stent: updated proposal of an algorithm for the choice of oral anticoagulant and its dose","volume":"40","author":"Rubboli","year":"2017","journal-title":"Eur J Intern Med"},{"key":"2022051906294101600_suac020-B87","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1093\/eurheartj\/ehx531","article-title":"The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum","volume":"38","author":"McCarthy","year":"2017","journal-title":"Eur Heart J"},{"key":"2022051906294101600_suac020-B88","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2174\/1381612822666161205113119","article-title":"Antiplatelet and anticoagulation treatment in patients with thrombocytopenia","volume":"23","author":"Morici","year":"2017","journal-title":"Curr Pharm Des"},{"key":"2022051906294101600_suac020-B89","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1016\/j.jcin.2018.05.033","article-title":"Impact of chronic thrombocytopenia on in-hospital outcomes after percutaneous coronary intervention","volume":"11","author":"Ayoub","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"2022051906294101600_suac020-B90","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/CIRCULATIONAHA.108.827162","article-title":"Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice","volume":"119","author":"Wang","year":"2009","journal-title":"Circulation"},{"key":"2022051906294101600_suac020-B91","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.3390\/jcm9082673","article-title":"Optimal antithrombotic treatment of patients with atrial fibrillation early after an acute coronary syndrome-triple therapy, dual antithrombotic therapy with an anticoagulant or, rather, temporary dual antiplatelet therapy?","volume":"9","author":"Limbruno","year":"2020","journal-title":"J Clin Med"},{"key":"2022051906294101600_suac020-B92","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijcard.2018.07.133","article-title":"Antithrombotic therapy for patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention with stent: the case of venous thromboembolism","volume":"269","author":"Riva","year":"2018","journal-title":"Int J Cardiol"},{"key":"2022051906294101600_suac020-B93","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"2022051906294101600_suac020-B94","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.amjcard.2019.11.029","article-title":"Comparison of the effect of age (&lt; 75 versus 75) on the efficacy and safety of dual therapy (dabigatran + clopidogrel or ticagrelor) versus triple therapy (warfarin + aspirin + clopidogrel or ticagrelor) in patients with atrial fibrillation after percutaneous coronary intervention (from the RE-DUAL PCI Trial)","volume":"125","author":"Ten Berg JM, Steg PG, Bhatt DL, Hohnloser SH, de Veer A, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Cannon CP; RE-DUAL PCI Steering Committee and Investigators.","year":"2020","journal-title":"Am J Cardiol"},{"key":"2022051906294101600_suac020-B95","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-021-00488-4","article-title":"Modulating the intensity of oral anticoagulation therapy with direct oral anticoagulants: feasible or not?","author":"Rubboli","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"2022051906294101600_suac020-B96","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease, developed in collaboration with EACTS","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2022051906294101600_suac020-B97","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.113.004834","article-title":"Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking oral anticoagulant. A nationwide cohort study","volume":"129","author":"Lamberts","year":"2014","journal-title":"Circulation"},{"key":"2022051906294101600_suac020-B98","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"2022051906294101600_suac020-B99","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ijcard.2018.06.098","article-title":"Outcomes of anticoagulated patients with atrial fibrillation treated with or with-out antiplatelet therapy\u2014a pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries","volume":"270","author":"Patti","year":"2018","journal-title":"Int J Cardiol"},{"key":"2022051906294101600_suac020-B100","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N Engl J Med"},{"key":"2022051906294101600_suac020-B101","doi-asserted-by":"crossref","first-page":"e020907","DOI":"10.1161\/JAHA.121.020907","article-title":"Antithrombotic therapy for atrial fibrillation and coronary artery disease in patients with prior atherothrombotic disease: a post hoc analysis of the AFIRE trial","volume":"10","author":"Matsuzawa Y, Kimura K, Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators.","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2022051906294101600_suac020-B102","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1016\/j.jcin.2021.07.045","article-title":"Rivaroxaban monotherapy in patients with atrial fibrillation after coronary stenting: insights from the AFIRE trial","volume":"14","author":"Matoba","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2022051906294101600_suac020-B103","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCULATIONAHA.118.036768","article-title":"Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation OAC-ALONE study","volume":"139","author":"Matsumura-Nakano","year":"2019","journal-title":"Circulation"},{"key":"2022051906294101600_suac020-B104","first-page":"3721791","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","author":"Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators.","year":"2015","journal-title":"N Engl J Med"},{"key":"2022051906294101600_suac020-B105","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/24\/Supplement_C\/C254\/43748855\/suac020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/24\/Supplement_C\/C254\/43748855\/suac020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T14:46:57Z","timestamp":1675608417000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/24\/Supplement_C\/C254\/6587929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":105,"journal-issue":{"issue":"Supplement_C","published-online":{"date-parts":[[2022,5,18]]},"published-print":{"date-parts":[[2022,5,18]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/suac020","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"type":"print","value":"1520-765X"},{"type":"electronic","value":"1554-2815"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,5,1]]}}}